{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T21:14:05Z","timestamp":1793826845846,"version":"4.6.1"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,14]],"date-time":"2022-06-14T00:00:00Z","timestamp":1655164800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,14]],"date-time":"2022-06-14T00:00:00Z","timestamp":1655164800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Cell Int"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Thrombospondin-2 (THBS2) is a versatile glycoprotein that regulates numerous biological functions, including the apoptosis-proliferation balance in endothelial cells, and it has been linked to tumor angiogenesis. However, the exact role of THBS2 in human cancer remains unknown. This study aimed to determine THBS2 expression in a pan-cancer analysis and its association with pan-cancer prognosis and to further identify its possible roles in tumor immunity and the extracellular matrix (ECM).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Data on THBS2 expression in cancers and normal tissues were downloaded from the Genotype-Tissue Expression portal and UCSC Xena visual exploration tool and analyzed using the ONCOMINE database, Perl programming language, and Gene Expression Profiling and Interactive Analyses vision 2 webserver. In addition, survival prognosis was analyzed using the survival, survminer, limma, and forestplot packages in R v. 4.0.3.Immune and matrix components were also analyzed using R v. 4.0.3. Most importantly, we partially validated the role and mechanism of THBS2 in pancreatic and gastric cancers in vitro using PANC1 and BGC-823 cell lines.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>THBS2 was significantly overexpressed in 17 of the 33 investigated cancers and linked to a poor prognosis in pan-cancer survival analysis. High THBS2 expression was an independent unfavorable prognostic factor in kidney renal papillary cell, mesothelioma, and stomach and pancreatic adenocarcinomas. Immune infiltration and THBS2 expression were also related. THBS2 expression has been linked to immune and stromal scores and immune checkpoint markers in various cancers. The protein\u2013protein interaction network revealed that THBS2 is associated with multiple ECM and immune proteins. THBS2 knockdown decreased the expression of CD47 and matrix metallopeptidase 2 (MMP-2) as well as the proliferation, migration, and invasion of PANC1 and BGC-823 cells in vitro.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Our findings suggested that THBS2 might promote cancer progression by remodeling the tumor microenvironment, affecting CD47-mediated signaling pathways, activating the pro-tumor functions of a disintegrin and metalloproteinase with thrombospondin motifs, and enhancing MMP-2 expression. Furthermore, it functions as a bridge between the ECM and immune infiltration in cancer and serves as a potential prognostic biomarker for several cancers, especially pancreatic and gastric adenocarcinomas.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12935-022-02622-x","type":"journal-article","created":{"date-parts":[[2022,6,14]],"date-time":"2022-06-14T09:03:43Z","timestamp":1655197423000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":56,"title":["Thrombospondin-2 acts as a bridge between tumor extracellular matrix and immune infiltration in pancreatic and stomach adenocarcinomas: an integrative pan-cancer analysis"],"prefix":"10.1186","volume":"22","author":[{"given":"Xingchen","family":"Liao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baoping","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiyun","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,14]]},"reference":[{"issue":"6","key":"2622_CR1","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/j.biocel.2004.01.004","volume":"36","author":"JC Adams","year":"2004","unstructured":"Adams JC, Lawler J. The thrombospondins. Int J Biochem Cell Biol. 2004;36(6):961\u20138.","journal-title":"Int J Biochem Cell Biol"},{"issue":"5","key":"2622_CR2","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.7150\/thno.29247","volume":"9","author":"AW Berger","year":"2019","unstructured":"Berger AW, Schwerdel D, Reinacher-Schick A, Uhl W, Algul H, Friess H, et al. A blood-based multi marker assay supports the differential diagnosis of early-stage pancreatic cancer. Theranostics. 2019;9(5):1280\u20137.","journal-title":"Theranostics"},{"key":"2622_CR3","first-page":"2483964","volume":"2021","author":"L Li","year":"2021","unstructured":"Li L, Dong J, Fu L, Xia X, Pan F, Ning Y. clinical value of serum thrombospondin-2 combined with CA19-9 in early diagnosis of gastric cancer. J Oncol. 2021;2021:2483964.","journal-title":"J Oncol"},{"key":"2622_CR4","doi-asserted-by":"publisher","first-page":"33366","DOI":"10.1038\/srep33366","volume":"6","author":"X Wang","year":"2016","unstructured":"Wang X, Zhang L, Li H, Sun W, Zhang H, Lai M. THBS2 is a potential prognostic biomarker in colorectal cancer. Sci Rep. 2016;6:33366.","journal-title":"Sci Rep"},{"issue":"4","key":"2622_CR5","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/j.immuni.2013.10.003","volume":"39","author":"G Bindea","year":"2013","unstructured":"Bindea G, Mlecnik B, Tosolini M, Kirilovsky A, Waldner M, Obenauf AC, et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity. 2013;39(4):782\u201395.","journal-title":"Immunity"},{"issue":"9","key":"2622_CR6","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1136\/gutjnl-2019-318419","volume":"68","author":"Y Zhu","year":"2019","unstructured":"Zhu Y, Yang J, Xu D, Gao XM, Zhang Z, Hsu JL, et al. Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade. Gut. 2019;68(9):1653\u201366.","journal-title":"Gut"},{"issue":"8","key":"2622_CR7","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/nrc.2017.51","volume":"17","author":"M De Palma","year":"2017","unstructured":"De Palma M, Biziato D, Petrova TV. Microenvironmental regulation of tumour angiogenesis. Nat Rev Cancer. 2017;17(8):457\u201374.","journal-title":"Nat Rev Cancer"},{"issue":"7","key":"2622_CR8","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1038\/nrd.2018.102","volume":"17","author":"M Cully","year":"2018","unstructured":"Cully M. Cancer: re-educating tumour-associated macrophages with nanoparticles. Nat Rev Drug Discov. 2018;17(7):468.","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"2622_CR9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0229955","volume":"15","author":"TF He","year":"2020","unstructured":"He TF, Yost SE, Frankel PH, Dagis A, Cao Y, Wang R, et al. Multi-panel immunofluorescence analysis of tumor infiltrating lymphocytes in triple negative breast cancer: evolution of tumor immune profiles and patient prognosis. PLoS ONE. 2020;15(3): e0229955.","journal-title":"PLoS ONE"},{"issue":"3","key":"2622_CR10","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1093\/ejcts\/ezaa098","volume":"58","author":"G Bocchialini","year":"2020","unstructured":"Bocchialini G, Lagrasta C, Madeddu D, Mazzaschi G, Marturano D, Sogni F, et al. Spatial architecture of tumour-infiltrating lymphocytes as a prognostic parameter in resected non-small-cell lung cancer. Eur J Cardiothorac Surg. 2020;58(3):619\u201328.","journal-title":"Eur J Cardiothorac Surg"},{"issue":"7655","key":"2622_CR11","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nature22396","volume":"545","author":"SR Gordon","year":"2017","unstructured":"Gordon SR, Maute RL, Dulken BW, Hutter G, George BM, McCracken MN, et al. PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity. Nature. 2017;545(7655):495\u20139.","journal-title":"Nature"},{"key":"2622_CR12","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.2147\/CMAR.S245425","volume":"12","author":"Y Cheng","year":"2020","unstructured":"Cheng Y, Wang T, Lv X, Li R, Yuan L, Shen J, et al. Detection of PD-L1 expression and its clinical significance in circulating tumor cells from patients with non-small-cell lung cancer. Cancer Manag Res. 2020;12:2069\u201378.","journal-title":"Cancer Manag Res"},{"key":"2622_CR13","doi-asserted-by":"publisher","first-page":"441","DOI":"10.3389\/fphar.2020.00441","volume":"11","author":"L Chocarro de Erauso","year":"2020","unstructured":"Chocarro de Erauso L, Zuazo M, Arasanz H, Bocanegra A, Hernandez C, Fernandez G, et al. Resistance to PD-L1\/PD-1 blockade immunotherapy . A tumor-intrinsic or tumor-extrinsic phenomenon. Front Pharmacol. 2020;11:441.","journal-title":"Front Pharmacol"},{"issue":"7","key":"2622_CR14","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1038\/s41587-019-0114-2","volume":"37","author":"AM Newman","year":"2019","unstructured":"Newman AM, Steen CB, Liu CL, Gentles AJ, Chaudhuri AA, Scherer F, et al. Determining cell type abundance and expression from bulk tissues with digital cytometry. Nat Biotechnol. 2019;37(7):773\u201382.","journal-title":"Nat Biotechnol"},{"issue":"1","key":"2622_CR15","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/nrc1782","volume":"6","author":"KE de Visser","year":"2006","unstructured":"de Visser KE, Eichten A, Coussens LM. Paradoxical roles of the immune system during cancer development. Nat Rev Cancer. 2006;6(1):24\u201337.","journal-title":"Nat Rev Cancer"},{"key":"2622_CR16","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.ejca.2018.06.023","volume":"101","author":"L Bonanno","year":"2018","unstructured":"Bonanno L, Pavan A, Dieci MV, Di Liso E, Schiavon M, Comacchio G, et al. The role of immune microenvironment in small-cell lung cancer: distribution of PD-L1 expression and prognostic role of FOXP3-positive tumour infiltrating lymphocytes. Eur J Cancer. 2018;101:191\u2013200.","journal-title":"Eur J Cancer"},{"key":"2622_CR17","doi-asserted-by":"publisher","first-page":"421","DOI":"10.3389\/fonc.2019.00421","volume":"9","author":"H Cheng","year":"2019","unstructured":"Cheng H, Wang Z, Fu L, Xu T. Macrophage polarization in the development and progression of ovarian cancers: an overview. Front Oncol. 2019;9:421.","journal-title":"Front Oncol"},{"issue":"4","key":"2622_CR18","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1007\/s10120-015-0579-8","volume":"19","author":"T Yamaguchi","year":"2016","unstructured":"Yamaguchi T, Fushida S, Yamamoto Y, Tsukada T, Kinoshita J, Oyama K, et al. Tumor-associated macrophages of the M2 phenotype contribute to progression in gastric cancer with peritoneal dissemination. Gastric Cancer. 2016;19(4):1052\u201365.","journal-title":"Gastric Cancer"},{"key":"2622_CR19","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1146\/annurev-immunol-041015-055605","volume":"34","author":"CG Vinuesa","year":"2016","unstructured":"Vinuesa CG, Linterman MA, Yu D, MacLennan IC. Follicular helper T Cells. Annu Rev Immunol. 2016;34:335\u201368.","journal-title":"Annu Rev Immunol"},{"issue":"15","key":"2622_CR20","doi-asserted-by":"publisher","first-page":"3678","DOI":"10.3390\/cancers13153678","volume":"13","author":"X Lin","year":"2021","unstructured":"Lin X, Ye L, Wang X, Liao Z, Dong J, Yang Y, et al. Follicular helper T Cells remodel the immune microenvironment of pancreatic cancer via secreting CXCL13 and IL-21. Cancers (Basel). 2021;13(15):3678.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"2622_CR21","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s12943-020-01238-x","volume":"19","author":"SY Wu","year":"2020","unstructured":"Wu SY, Fu T, Jiang YZ, Shao ZM. Natural killer cells in cancer biology and therapy. Mol Cancer. 2020;19(1):120.","journal-title":"Mol Cancer"},{"issue":"3","key":"2622_CR22","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.cels.2018.03.003","volume":"6","author":"FX Schaub","year":"2018","unstructured":"Schaub FX, Dhankani V, Berger AC, Trivedi M, Richardson AB, Shaw R, et al. Pan-cancer alterations of the MYC oncogene and its proximal network across the cancer genome atlas. Cell Syst. 2018;6(3):282-300.e282.","journal-title":"Cell Syst"},{"key":"2622_CR23","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.cca.2021.03.022","volume":"518","author":"S Zou","year":"2021","unstructured":"Zou S, Li J, Yan J, Xu J, Lin M, Cao D. Distribution of serum Thrombospondin-2, a novel tumor marker, in general population and cancer patients in China. Clin Chim Acta. 2021;518:123\u20137.","journal-title":"Clin Chim Acta"},{"issue":"3","key":"2622_CR24","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1245\/s10434-018-07109-6","volume":"26","author":"HY Peng","year":"2019","unstructured":"Peng HY, Chang MC, Hu CM, Yang HI, Lee WH, Chang YT. Thrombospondin-2 is a highly specific diagnostic marker and is associated with prognosis in pancreatic cancer. Ann Surg Oncol. 2019;26(3):807\u201314.","journal-title":"Ann Surg Oncol"},{"issue":"7","key":"2622_CR25","doi-asserted-by":"publisher","first-page":"BSR20190476","DOI":"10.1042\/BSR20190476","volume":"39","author":"YM Jiang","year":"2019","unstructured":"Jiang YM, Yu DL, Hou GX, Jiang JL, Zhou Q, Xu XF. Serum thrombospondin-2 is a candidate diagnosis biomarker for early non-small-cell lung cancer. Biosci Rep. 2019;39(7):BSR20190476.","journal-title":"Biosci Rep"},{"issue":"54","key":"2622_CR26","doi-asserted-by":"publisher","first-page":"92254","DOI":"10.18632\/oncotarget.21173","volume":"8","author":"W Fei","year":"2017","unstructured":"Fei W, Chen L, Chen J, Shi Q, Zhang L, Liu S, et al. RBP4 and THBS2 are serum biomarkers for diagnosis of colorectal cancer. Oncotarget. 2017;8(54):92254\u201364.","journal-title":"Oncotarget"},{"issue":"7467","key":"2622_CR27","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/nature12626","volume":"501","author":"MR Junttila","year":"2013","unstructured":"Junttila MR, de Sauvage FJ. Influence of tumour micro-environment heterogeneity on therapeutic response. Nature. 2013;501(7467):346\u201354.","journal-title":"Nature"},{"issue":"1","key":"2622_CR28","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/nrc.2015.5","volume":"16","author":"MG Morvan","year":"2016","unstructured":"Morvan MG, Lanier LL. NK cells and cancer: you can teach innate cells new tricks. Nat Rev Cancer. 2016;16(1):7\u201319.","journal-title":"Nat Rev Cancer"},{"issue":"11","key":"2622_CR29","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1038\/ni1102-991","volume":"3","author":"GP Dunn","year":"2002","unstructured":"Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002;3(11):991\u20138.","journal-title":"Nat Immunol"},{"issue":"3","key":"2622_CR30","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1007\/s11033-020-05253-5","volume":"47","author":"F Tang","year":"2020","unstructured":"Tang F, Xu Y, Zhao B. NLRC5: new cancer buster? Mol Biol Rep. 2020;47(3):2265\u201377.","journal-title":"Mol Biol Rep"},{"issue":"21","key":"2622_CR31","doi-asserted-by":"publisher","first-page":"8359","DOI":"10.3390\/ijms21218359","volume":"21","author":"A Simiczyjew","year":"2020","unstructured":"Simiczyjew A, Dratkiewicz E, Mazurkiewicz J, Zietek M, Matkowski R, Nowak D. The Influence of tumor microenvironment on immune escape of melanoma. Int J Mol Sci. 2020;21(21):8359.","journal-title":"Int J Mol Sci"},{"issue":"16","key":"2622_CR32","doi-asserted-by":"publisher","first-page":"R921","DOI":"10.1016\/j.cub.2020.06.081","volume":"30","author":"NM Anderson","year":"2020","unstructured":"Anderson NM, Simon MC. The tumor microenvironment. Curr Biol. 2020;30(16):R921\u20135.","journal-title":"Curr Biol"},{"key":"2622_CR33","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0000000000004037","author":"H Zhang","year":"2020","unstructured":"Zhang H, Li R, Cao Y, Gu Y, Lin C, Liu X, et al. Poor clinical outcomes and immunoevasive contexture in intratumoral IL-10-producing macrophages enriched gastric cancer patients. Ann Sur. 2020. https:\/\/doi.org\/10.1097\/SLA.0000000000004037.","journal-title":"Ann Sur"},{"issue":"2","key":"2622_CR34","first-page":"133","volume":"33","author":"J Choi","year":"2018","unstructured":"Choi J, Gyamfi J, Jang H, Koo JS. The role of tumor-associated macrophage in breast cancer biology. Histol Histopathol. 2018;33(2):133\u201345.","journal-title":"Histol Histopathol"},{"issue":"9","key":"2622_CR35","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/s41568-020-0281-y","volume":"20","author":"S Jaillon","year":"2020","unstructured":"Jaillon S, Ponzetta A, Di Mitri D, Santoni A, Bonecchi R, Mantovani A. Neutrophil diversity and plasticity in tumour progression and therapy. Nat Rev Cancer. 2020;20(9):485\u2013503.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"2622_CR36","doi-asserted-by":"publisher","first-page":"5099","DOI":"10.1038\/s41467-018-07505-2","volume":"9","author":"CM Rice","year":"2018","unstructured":"Rice CM, Davies LC, Subleski JJ, Maio N, Gonzalez-Cotto M, Andrews C, et al. Tumour-elicited neutrophils engage mitochondrial metabolism to circumvent nutrient limitations and maintain immune suppression. Nat Commun. 2018;9(1):5099.","journal-title":"Nat Commun"},{"issue":"1","key":"2622_CR37","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1038\/s41467-020-20447-y","volume":"12","author":"X Wang","year":"2021","unstructured":"Wang X, Hu LP, Qin WT, Yang Q, Chen DY, Li Q, et al. Identification of a subset of immunosuppressive P2RX1-negative neutrophils in pancreatic cancer liver metastasis. Nat Commun. 2021;12(1):174.","journal-title":"Nat Commun"},{"issue":"3","key":"2622_CR38","doi-asserted-by":"publisher","first-page":"302","DOI":"10.7150\/ijbs.14996","volume":"12","author":"K Felix","year":"2016","unstructured":"Felix K, Gaida MM. Neutrophil-derived proteases in the microenvironment of pancreatic cancer -active players in tumor progression. Int J Biol Sci. 2016;12(3):302\u201313.","journal-title":"Int J Biol Sci"},{"issue":"6409","key":"2622_CR39","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1126\/science.aao4227","volume":"361","author":"J Albrengues","year":"2018","unstructured":"Albrengues J, Shields MA, Ng D, Park CG, Ambrico A, Poindexter ME, et al. Neutrophil extracellular traps produced during inflammation awaken dormant cancer cells in mice. Science. 2018;361(6409):227.","journal-title":"Science"},{"issue":"5","key":"2622_CR40","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.semcancer.2008.03.004","volume":"18","author":"A Sica","year":"2008","unstructured":"Sica A, Larghi P, Mancino A, Rubino L, Porta C, Totaro MG, et al. Macrophage polarization in tumour progression. Semin Cancer Biol. 2008;18(5):349\u201355.","journal-title":"Semin Cancer Biol"},{"issue":"12","key":"2622_CR41","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1007\/s00262-017-2052-5","volume":"66","author":"XL Fu","year":"2017","unstructured":"Fu XL, Duan W, Su CY, Mao FY, Lv YP, Teng YS, et al. Interleukin 6 induces M2 macrophage differentiation by STAT3 activation that correlates with gastric cancer progression. Cancer Immunol Immunother. 2017;66(12):1597\u2013608.","journal-title":"Cancer Immunol Immunother"},{"key":"2622_CR42","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1146\/annurev-pathmechdis-012418-013058","volume":"16","author":"S Ugel","year":"2021","unstructured":"Ugel S, Can\u00e8 S, De Sanctis F, Bronte V. Monocytes in the tumor microenvironment. Annu Rev Pathol. 2021;16:93\u2013122.","journal-title":"Annu Rev Pathol"},{"key":"2622_CR43","doi-asserted-by":"publisher","first-page":"424","DOI":"10.3389\/fonc.2020.00424","volume":"10","author":"KW Bi","year":"2020","unstructured":"Bi KW, Wei XG, Qin XX, Li B. BTK Has potential to be a prognostic factor for lung adenocarcinoma and an indicator for tumor microenvironment remodeling: a study based on TCGA data mining. Front Oncol. 2020;10:424.","journal-title":"Front Oncol"},{"key":"2622_CR44","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.16463","author":"KY Chou","year":"2021","unstructured":"Chou KY, Chang AC, Ho CY, Tsai TF, Chen HE, Chen PC, et al. Thrombospondin-4 promotes bladder cancer cell migration and invasion via MMP2 production. J Cell Mol Med. 2021. https:\/\/doi.org\/10.1111\/jcmm.16463.","journal-title":"J Cell Mol Med"},{"issue":"1","key":"2622_CR45","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1111\/cas.12309","volume":"105","author":"X Ni","year":"2014","unstructured":"Ni X, Xia T, Zhao Y, Zhou W, Wu N, Liu X, et al. Downregulation of miR-106b induced breast cancer cell invasion and motility in association with overexpression of matrix metalloproteinase 2. Cancer Sci. 2014;105(1):18\u201325.","journal-title":"Cancer Sci"},{"issue":"3","key":"2622_CR46","doi-asserted-by":"publisher","first-page":"911","DOI":"10.3892\/or.2020.7910","volume":"45","author":"KY Chou","year":"2021","unstructured":"Chou KY, Chang AC, Tsai TF, Lin YC, Chen HE, Ho CY, et al. MicroRNA34a5p serves as a tumor suppressor by regulating the cell motility of bladder cancer cells through matrix metalloproteinase2 silencing. Oncol Rep. 2021;45(3):911\u201320.","journal-title":"Oncol Rep"},{"issue":"6","key":"2622_CR47","doi-asserted-by":"publisher","first-page":"661","DOI":"10.3109\/07357901003735634","volume":"28","author":"Q Qian","year":"2010","unstructured":"Qian Q, Wang Q, Zhan P, Peng L, Wei SZ, Shi Y, et al. The role of matrix metalloproteinase 2 on the survival of patients with non-small cell lung cancer: a systematic review with meta-analysis. Cancer Invest. 2010;28(6):661\u20139.","journal-title":"Cancer Invest"},{"issue":"1","key":"2622_CR48","doi-asserted-by":"publisher","first-page":"1754094","DOI":"10.1080\/2162402X.2020.1754094","volume":"9","author":"C Hoffmann","year":"2020","unstructured":"Hoffmann C, Vacher S, Sirven P, Lecerf C, Massenet L, Moreira A, et al. MMP2 as an independent prognostic stratifier in oral cavity cancers. Oncoimmunology. 2020;9(1):1754094.","journal-title":"Oncoimmunology"},{"issue":"6","key":"2622_CR49","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0198896","volume":"13","author":"Y Shi","year":"2018","unstructured":"Shi Y, Su C, Hu H, Yan H, Li W, Chen G, et al. Serum MMP-2 as a potential predictive marker for papillary thyroid carcinoma. PLoS ONE. 2018;13(6): e0198896.","journal-title":"PLoS ONE"},{"issue":"3","key":"2622_CR50","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1007\/s00404-016-4257-9","volume":"295","author":"H Jia","year":"2017","unstructured":"Jia H, Zhang Q, Liu F, Zhou D. Prognostic value of MMP-2 for patients with ovarian epithelial carcinoma: a systematic review and meta-analysis. Arch Gynecol Obstet. 2017;295(3):689\u201396.","journal-title":"Arch Gynecol Obstet"},{"key":"2622_CR51","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.matbio.2015.01.013","volume":"44\u201346","author":"S Cal","year":"2015","unstructured":"Cal S, L\u00f3pez-Ot\u00edn C. ADAMTS proteases and cancer. Matrix Biol. 2015;44\u201346:77\u201385.","journal-title":"Matrix Biol"},{"issue":"Pt 2","key":"2622_CR52","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.semcancer.2017.10.001","volume":"52","author":"S Burugu","year":"2018","unstructured":"Burugu S, Dancsok AR, Nielsen TO. Emerging targets in cancer immunotherapy. Semin Cancer Biol. 2018;52(Pt 2):39\u201352.","journal-title":"Semin Cancer Biol"},{"issue":"7","key":"2622_CR53","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1007\/s00262-020-02806-2","volume":"70","author":"M Shi","year":"2021","unstructured":"Shi M, Gu Y, Jin K, Fang H, Chen Y, Cao Y, et al. CD47 expression in gastric cancer clinical correlates and association with macrophage infiltration. Cancer Immunol Immunother. 2021;70(7):1831\u201340.","journal-title":"Cancer Immunol Immunother"},{"key":"2622_CR54","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.ejca.2017.02.013","volume":"76","author":"K Weiskopf","year":"2017","unstructured":"Weiskopf K. Cancer immunotherapy targeting the CD47\/SIRP\u03b1 axis. Eur J Cancer. 2017;76:100\u20139.","journal-title":"Eur J Cancer"}],"container-title":["Cancer Cell International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-022-02622-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12935-022-02622-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-022-02622-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,14]],"date-time":"2022-06-14T12:07:24Z","timestamp":1655208444000},"score":1,"resource":{"primary":{"URL":"https:\/\/cancerci.biomedcentral.com\/articles\/10.1186\/s12935-022-02622-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,14]]},"references-count":54,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2622"],"URL":"https:\/\/doi.org\/10.1186\/s12935-022-02622-x","relation":{},"ISSN":["1475-2867"],"issn-type":[{"value":"1475-2867","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,14]]},"assertion":[{"value":"23 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"213"}}